Tempus AI (TEM) said Tuesday that results of a new study show that its Immune Profile Score algorithmic test predicts outcomes for patients receiving immune checkpoint inhibitors more accurately than conventional biomarkers.
The company said the results show that the test "consistently" outperformed conventional biomarkers, and can help physicians identify the patients who are most likely to benefit from immunotherapy.
Tempus shares were 0.7% higher in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments